Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Efaproxiral. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efaproxiral SCHEMBL3768310 | 0.99 | PPARA (0.52) | PPARAPPARGALDH1A1MEN1KMT2A | |
| SCHEMBL12998270 | 0.90 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AL3MBTL1NLRP3 | |
| SCHEMBL12998281 | 0.89 | HPGD (0.62) | PPARAPPARGALDH1A1MEN1KMT2A | |
| SCHEMBL6558056 | 0.88 | SMN1; SMN2 (0.58) | PPARAPPARGALDH1A1MEN1KMT2A | |
| SCHEMBL14341054 | 0.88 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AL3MBTL1NLRP3 | |
| SCHEMBL29079329 | 0.88 | PPARA (0.56) | PPARAPPARGALDH1A1KMT2ARAB9A | |
| Efaproxiral SCHEMBL3763811 | 0.88 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AL3MBTL1NLRP3 | |
| SCHEMBL12998285 | 0.86 | PPARA (0.53) | PPARAPPARGALDH1A1MEN1KMT2A | |
| SCHEMBL6353457 | 0.86 | ALDH1A1 (0.45) | PPARAPPARGALDH1A1MEN1KMT2A | |
| SCHEMBL6556141 | 0.86 | PPARA (0.61) | PPARAPPARGALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1000 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| EP-4687863-A1 | RADIOPROTECTION BY INHIBITION OF SUPEROXIDE DISMUTASE 1 | Deutsches Krebsforschungszentrum (DE) | 2026-02-11 | — | — | EP | claimed |
| EP-4612132-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | Sitryx Therapeutics Limited (GB) | 2025-09-10 | — | — | EP | claimed |
| US-20250276046-A1 | SELF-ASSEMBLING OXYGEN CARRIER COMPOSITIONS | KaloCyte (US) | 2025-09-04 | — | — | US | claimed |
| CN-120166987-A | Phthalazine derivatives as pyruvate kinase modulators | 西特瑞治疗有限公司 | 2025-06-17 | — | — | CN | claimed |
| US-20250177423-A1 | PHOTORESPONSIVE PEPTIDE DELIVERY SYSTEM AND METHOD OF USING THE SAME | THE UNIVERSITY OF HONG KONG (CN) | 2025-06-05 | — | — | US | claimed |
| US-12280050-B2 | Therapeutic compositions, combinations, and methods of use | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-04-22 | — | — | US | claimed |
| US-12257289-B2 | Self-assembling oxygen carrier compositions | KaloCyte, Inc. (US) | 2025-03-25 | — | — | US | claimed |
| WO-2024208828-A1 | RADIOPROTECTION BY INHIBITION OF SUPEROXIDE DISMUTASE 1 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2024-10-10 | — | — | WO | claimed |
| WO-1999049847-A1 | NEUROPROTECTIVE COMPOSITION | ALLOS THERAPEUTICS, INC. (US) | 1999-10-07 | — | — | WO | claimed |
| WO-1999048490-A1 | ALLOSTERIC INHIBITORS AND ACTIVATORS OF PYRUVATE KINASE | ALLOS THERAPEUTICS, INC. (US) | 1999-09-30 | — | — | WO | claimed |
| US-5927283-A | TREATING DISEASES INVOLVING OXYGEN DEFICIENCY, IN WOUND HEALING, AND IN RESTORING OXYGEN AFFINITY OF STORED BLOOD. | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-07-27 | — | — | US | claimed |
| US-5827888-A | ADMINISTERING 2-(4-((((3,5-DIMETHYLPHENYL)AMINO)CARBONYL)METHYL)PHENOXY)-2-M ETHYL PROPIONIC ACID | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1998-10-27 | — | — | US | claimed |
| US-5705521-A | Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1998-01-06 | — | — | US | claimed |
| US-5677330-A | THERAPY HYPOXIA, HYPOTHERMIA, ISCHEMIC, WOUNDS, ULCERS, TISSUE TRANSPLANTS, SESPIS | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1997-10-14 | — | — | US | claimed |
| WO-1997034594-A2 | USE OF ALLOSTERIC HAEMOGLOBIN MODIFIER FOR TREATING SOLID TUMORS AND INHIBITING TUMOR METASTASES | DANA-FARBER CANCER INSTITUTE (US) | 1997-09-25 | — | — | WO | claimed |
| US-5648375-A | Use of hydrophobic compounds and anesthetics in combination with allosteric hemoglobin modifiers | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1997-07-15 | — | — | US | claimed |
| US-5525630-A | ADMINISTERING TO PATIENT SUFFICIENT DOSAGE OF 2-(4-((((3,5-DIMETHYLPHENYL)AMINO)CARBONYL)METHYL)PHENOXY)-2-METHYL PROPIONIC ACID TO CLEAR CARBON MONOXIDE-HEMOGLOBIN FORM BLOOD STREAM | ALLOS THERAPEUTICS, INC. (US) | 1996-06-11 | — | — | US | claimed |
| US-5122539-A | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-06-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | PDK1, PDK2, PDK4 | PPARA 315/4885PPARG 199/4885ALDH1A1 629/4885 |
| US-12257289-B2 | Self-assembling oxygen carrier compositions | HBG2, HBG1, HBB | PPARA 716/4885PPARG 883/4885ALDH1A1 3918/4885 |
| US-20250177423-A1 | PHOTORESPONSIVE PEPTIDE DELIVERY SYSTEM AND METHOD OF USING THE SAME | DNPEP, LNPEP, VIP | PPARA 2346/4885PPARG 3900/4885ALDH1A1 2634/4885 |
| US-20250276046-A1 | SELF-ASSEMBLING OXYGEN CARRIER COMPOSITIONS | HBG2, HBG1, HBB | PPARA 716/4885PPARG 883/4885ALDH1A1 3918/4885 |
| US-12280050-B2 | Therapeutic compositions, combinations, and methods of use | BRAF, PTK2, NRAS | PPARA 4434/4885PPARG 4055/4885ALDH1A1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.